Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CB1 agonism prolongs therapeutic window for hormone replacement in ovariectomized mice
Kun Zhang, … , Shui-bing Liu, Ming-gao Zhao
Kun Zhang, … , Shui-bing Liu, Ming-gao Zhao
Published May 6, 2019
Citation Information: J Clin Invest. 2019;129(6):2333-2350. https://doi.org/10.1172/JCI123689.
View: Text | PDF
Research Article Endocrinology Neuroscience

CB1 agonism prolongs therapeutic window for hormone replacement in ovariectomized mice

  • Text
  • PDF
Abstract

Hormone therapy (HT) is reported to be deficient in improving learning and memory in older postmenopausal women according to recent clinical studies; however, the reason for failure is unknown. A “window of opportunity” for estrogen treatment is proposed to explain this deficiency. Here, we found that facilitation of memory extinction and long-term depression by 17β-estradiol (E2) was normal in mice 1 week after ovariectomy (OVXST), but it was impaired in mice 3 months after ovariectomy (OVXLT). High-throughput sequencing revealed a decrease of miR-221-5p, which promoted cannabinoid receptor 1 (CB1) ubiquitination by upregulation of Neurl1a/b in E2-treated OVXLT mice. Blood samples from postmenopausal women aged 56–65 indicated decreases of miR-221-5p and 2-arachidonoylglycerol compared with samples from perimenopausal women aged 46–55. Replenishing of miR-221-5p or treatment with a CB1 agonist rescued the impairment of fear extinction in E2-treated OVXLT mice. The present study demonstrates that an HT time window in mice can be prolonged by cotreatment with a CB1 agonist, implying a potential strategy for HT in long-term menopausal women.

Authors

Kun Zhang, Qi Yang, Le Yang, Yan-jiao Li, Xin-shang Wang, Yu-jiao Li, Rui-li Dang, Shao-yu Guan, Yan-yan Guo, Ting Sun, Yu-mei Wu, An Liu, Yan Zhang, Shui-bing Liu, Ming-gao Zhao

×

Figure 4

Decreased miR-221-5p after long-term estrogen deprivation.

Options: View larger image (or click on image) Download as PowerPoint
Decreased miR-221-5p after long-term estrogen deprivation.
(A) mRNA leve...
(A) mRNA levels of CB1 were similar among different mice. n = 8 mice in each group. (B) Volcano plots of miRNA sequencing from the mPFC between OVXLT + E2 and OVXST + E2 mice, OVXLT + E2 and sham mice, and OVXLT and OVXST mice. n = 3 mice per group. (C) Venn diagram shows the potential miRNAs among treatments. miR-221-5p and miR-541-3p were recognized as targets responsible for impaired fear memory extinction in OVXLT + E2 mice. (D) Levels of miR-221-5p and miR-541-3p in mPFC of different groups were confirmed by quantitative PCR. n = 6 mice per group. *P < 0.05, **P < 0.01 between the marked groups by 2-way ANOVA followed by Bonferroni’s post hoc test. (E) Levels of miR-221-5p and miR-541-3p in plasma from 25- to 35-year-old, 36- to 45-year-old, 46- to 55-year-old, and 56- to 65-year-old women. Right panel: Levels of miR-221-5p in plasma after years of menopause. (F) 2-AG (left), total E2 (middle), and free E2 (right) in plasma from different ages. (E and F) *P < 0.05, **P < 0.01 between the marked groups by 1-way ANOVA followed by Bonferroni’s post hoc test. Experimenters were not blinded to the treatment. Data are represented as mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts